Stock 000597 NORTHEAST PHARMACEUTICAL GROUP CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Northeast Pharmaceutical Group Co., Ltd.

Equities

000597

CNE0000009G0

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
4.66 CNY +1.75% Intraday chart for Northeast Pharmaceutical Group Co., Ltd. -0.43% -12.90%
Apr. 25 Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 01 Northeast Pharmaceutical Group Co., Ltd. Proposes Profit Distribution for 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 5,787 6,749 6,848 8,384 9,051 7,646
Enterprise Value (EV) 1 7,928 8,249 7,967 8,322 7,403 4,178
P/E ratio 28 x 39.3 x 507 x 88.9 x 25.2 x 21.4 x
Yield - - 0.16% 0.23% 1.58% 1.87%
Capitalization / Revenue 0.78 x 0.82 x 0.93 x 1.03 x 1.03 x 0.93 x
EV / Revenue 1.06 x 1 x 1.08 x 1.02 x 0.84 x 0.51 x
EV / EBITDA 16 x 13.2 x 11.6 x 11.6 x 9.9 x 4.62 x
EV / FCF 16.3 x 4.83 x 21.7 x 6.29 x 6.2 x 2.52 x
FCF Yield 6.13% 20.7% 4.6% 15.9% 16.1% 39.7%
Price to Book 1.67 x 1.77 x 1.72 x 2.02 x 1.99 x 1.53 x
Nbr of stocks (in thousands) 1,264,538 1,348,043 1,350,702 1,347,873 1,434,316 1,429,103
Reference price 2 4.576 5.007 5.070 6.220 6.310 5.350
Announcement Date 4/2/19 4/19/20 3/16/21 3/30/22 3/29/23 3/29/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 7,467 8,220 7,384 8,145 8,809 8,243
EBITDA 1 494.7 626.5 688.6 715.8 747.7 904.6
EBIT 1 174.8 290.1 213.6 210.6 219.6 366.2
Operating Margin 2.34% 3.53% 2.89% 2.59% 2.49% 4.44%
Earnings before Tax (EBT) 1 213.7 224.2 91.84 120.2 525.4 488.2
Net income 1 195.2 174 12.26 99.03 350.1 358.5
Net margin 2.61% 2.12% 0.17% 1.22% 3.97% 4.35%
EPS 2 0.1635 0.1275 0.0100 0.0700 0.2500 0.2500
Free Cash Flow 1 485.8 1,707 366.7 1,324 1,193 1,661
FCF margin 6.51% 20.76% 4.97% 16.25% 13.55% 20.14%
FCF Conversion (EBITDA) 98.19% 272.42% 53.25% 184.96% 159.6% 183.56%
FCF Conversion (Net income) 248.87% 981.06% 2,991.52% 1,336.83% 340.8% 463.24%
Dividend per Share - - 0.008000 0.0140 0.1000 0.1000
Announcement Date 4/2/19 4/19/20 3/16/21 3/30/22 3/29/23 3/29/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 2,141 1,500 1,119 - - -
Net Cash position 1 - - - 62.2 1,647 3,468
Leverage (Debt/EBITDA) 4.327 x 2.393 x 1.625 x - - -
Free Cash Flow 1 486 1,707 367 1,324 1,193 1,661
ROE (net income / shareholders' equity) 6.56% 4.54% 0.27% 2.27% 7.93% 7.62%
ROA (Net income/ Total Assets) 0.98% 1.49% 1.08% 1.04% 1.02% 1.57%
Assets 1 19,939 11,638 1,134 9,533 34,436 22,777
Book Value Per Share 2 2.740 2.830 2.950 3.070 3.180 3.490
Cash Flow per Share 2 1.020 1.130 1.100 1.890 2.680 3.950
Capex 1 566 229 400 120 244 235
Capex / Sales 7.58% 2.79% 5.42% 1.47% 2.77% 2.86%
Announcement Date 4/2/19 4/19/20 3/16/21 3/30/22 3/29/23 3/29/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
NORTHEAST PHARMACEUTICAL GROUP CO., LTD. Stock Northeast Pharmaceutical Group Co., Ltd.
-12.90% 920M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 664B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.38% 567B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 330B
ABBVIE INC. Stock AbbVie Inc.
+4.23% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.34% 234B
NOVARTIS AG Stock Novartis AG
+4.63% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-9.94% 196B
AMGEN INC. Stock Amgen Inc.
-4.04% 148B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 000597 Stock
  4. Financials Northeast Pharmaceutical Group Co., Ltd.